After two years in the doldrums, the stock is soaring. Moderna (MRNA 1.90%) isn't new to artificial intelligence (AI). The biotech best known for its billion-dollar coronavirus vaccine has been using this hot technology for years to help it save crucial time in the laboratory. For example, Moderna uses AI to produce mRNAs for researchers to work with, so they no longer have to create mRNA manually to run experiments. And last year, it signed a deal with International Business Machines to use its AI and quan ...

Moderna's RSV candidate First, a bit of background on Moderna's RSV candidate. RSV generally causes cold-like symptoms, but the virus could be severe for certain groups like elderly people or infants. Moderna is seeking approval for its vaccine in people over age 60 in various countries around the world, including the U.S. Last year, regulators approved two other RSV vaccines -- from GSK and Pfizer -- so Moderna isn't the only player in this field. But there's room for more than one, and Moderna may even ex ...

Shares of Moderna, Inc. (MRNA) were down 4.4% on May 10 after the company announced that the FDA has delayed the review timeline for its mRNA-based, respiratory syncytial virus (RSV) vaccine, mRNA-1345. Moderna has developed mRNA-1345 for use in older adults (aged 60 years and above). The regulatory body notified the company that due to administrative constraints, it would not be able to complete the review of the biologics license application (BLA) for mRNA-1345 by the Prescription Drug User Fee Act date o ...

Moderna (MRNA) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Over the past month, shares of this biotechnology company have returned +11.6%, compared to the Zacks S&P 500 composite's +1.3% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which Moderna falls in, has gained 0.8%. The key question now is: What could be the stock's future direction ...

This team-up is more than a PR stunt, but it might not be revolutionary.Moderna (MRNA) and OpenAI are collaborating to bring artificial intelligence (AI) to every level of the biotech's operations, and the implications could perhaps be significant for investors. If the lofty claims made by others in the biotech industry are true, the company could see a smattering of benefits that ultimately enable it to capture more earnings. And, at a time when its coronavirus vaccine revenue is no longer enough to make t ...

Key TakeawaysModerna said the Food and Drug Administration (FDA) has delayed its approval decision for the respiratory syncytial virus (RSV) vaccine.The biotech reported it was advised by regulators that their review wouldn't be completed until the end of the month, whereas previously it was expected on May 12.Moderna is moving to produce vaccines for other diseases now that demand for its COVID-19 shot has declined with the pandemic over. Moderna (MRNA) shares lost ground in intraday trading Friday as the ...

Moderna on Friday said the Food and Drug Administration has delayed the approval of its vaccine for respiratory syncytial virus to the end of May due to "administrative constraints" at the agency.The FDA was expected to make a decision on the RSV shot on Sunday. The agency has not informed Moderna of any issues related to the vaccine's safety, efficacy or quality that would prevent its approval, the biotech company said in a release.Investors are watching the upcoming approval closely as Moderna tries to re ...

The COVID-19 pandemic thrust this company's science -- and its stock -- into the spotlight.Five years ago, pharmaceutical company Moderna (MRNA 0.68%) was mostly unknown. It was developing vaccines that induce human immune cells to more effectively fight disease. But the science of DNA-based drugs was on the experimental fringe of the biopharma landscape. Not too many investors were looking to make such a bet.Then the COVID-19 pandemic materialized. As it turns out, the coronavirus was the ideal target for ...

Moderna (MRNA) stock broke out for the first time in over a year on May 2 after the biotech company notched a big quarterly beat on the back of its Covid vaccine.X During the quarter, the Covid vaccine called Spikevax brought in $167 million in sales, well above forecasts for $93 million, according to FactSet. Losses also came in better than expected at $3.07 per share, though reversed from a year-earlier gain.Notably, Moderna kept its outlook for the year.Later this month, the Food and Drug Administration ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _ to _ Commission File Number: 001-38753 Moderna, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 81-3467528 (State or Other Jurisdiction o ...